Note: This story was updated Nov. 18, 2021, to correct information about Pulmozyme’s administration method. Bronchitol (mannitol) plus Pulmozyme (dornase alfa) is better than Pulmozyme alone to help loosen mucus in the lungs in children with cystic fibrosis (CF), and this seems to translate into better lung function. The…
News
A branch of the European Medicines Agency (EMA) has recommended expanding Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to include children with cystic fibrosis (CF) as young as age 6 who have at least one F508del mutation. The recommendation, from the EMA’s Committee for Medicinal Products for Human Use (CHMP),…
People with cystic fibrosis (CF) who have mild depression or anxiety report heightened stress, with significantly lower scores on 10 of 12 measures of health-related life quality as compared with the general population of CF patients, new research shows. According to…
Despite longer hospital stays and higher costs, adults with cystic fibrosis (CF) do not have a greater risk of death from surgery to remove the gallbladder — called a cholecystectomy — compared with people who do not have CF, a study reported. “Importantly, we found that cholecystectomy had very…
Elexacaftor (VX-445), a next-generation CFTR corrector that is part of the triple-combination therapy Trikafta, is also a potentiator, a study reports. Results further showed that in combination with ivacaftor, sold as Kalydeco and also a potentiator, elexacaftor boosts ion flow across CFTR, the…
Use of inhaled hypertonic saline can lessen cystic fibrosis (CF)-related lung damage in young children with the disease, data from a clinical trial indicates. Based on these finding, “we can conclude that hypertonic saline is an effective, safe, and cheap treatment option for preschool children with CF,” said Harm Tiddens,…
Trikafta treatment can reduce the frequency of pulmonary exacerbations — times when lung symptoms get markedly worse — for people with cystic fibrosis (CF). That’s according to an analysis of real-world data shared at this year’s North American Cystic Fibrosis Conference (NACFC), in an oral presentation, “…
Personalized treatment with bacteria-infecting viruses, called bacteriophages, could be used to combat Pseudomonas aeruginosa, the main bacteria involved in lung infections in people with cystic fibrosis (CF), both by killing the bacteria and making them less resistant to antibiotics. Bacteriophage therapy “is safe, decreases P. aeruginosa titers [levels], and…
Treatment with Trikafta may improve nutritional status or lessen anemia among some people with cystic fibrosis (CF) who have received a lung transplant, but more research is needed to understand the potential benefits — and risks — of using the triple-combination medication in this particular patient population. That’s…
Treatment with Trikafta lowered the need for antibiotics and mucus-clearing therapies among children and adolescents with cystic fibrosis being followed at a pediatric CF center in Utah. Jeffery T. Zobell, a clinical pharmacist at Primary…
Your CF Community

Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Recent Posts
- This National Donate Life Month, let’s celebrate and honor our community
- New study shows sex impacts blood vessel health in people with CF
- The importance of telling someone they’ve had an impact on your life
- Bioversys partners with Hackensack to develop antibiotics for NTM treatments
- Liver-only transplant leads to better outcomes for kids with advanced CF